靶向白喉毒素治疗母细胞性浆细胞样树突状细胞肿瘤
Targeted diphtheria toxin to treat BPDCN.
作者信息
FitzGerald David J
机构信息
NATIONAL INSTITUTES OF HEALTH.
出版信息
Blood. 2014 Jul 17;124(3):310-2. doi: 10.1182/blood-2014-06-578633.
Abstract
In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
摘要
在本期《血液》杂志中，弗兰克尔等人描述了一种针对原始浆细胞样树突状细胞瘤（BPDCN）的新型治疗方法，该方法使用一种经过改造的白喉毒素，通过与白细胞介素（IL）3融合，靶向恶性细胞（见A组）。
相似文献
1
Targeted diphtheria toxin to treat BPDCN.靶向白喉毒素治疗母细胞性浆细胞样树突状细胞肿瘤
Blood. 2014 Jul 17;124(3):310-2. doi: 10.1182/blood-2014-06-578633.
2
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.针对白细胞介素-3受体的靶向疗法SL-401在母细胞样浆细胞样树突状细胞肿瘤患者中的活性。
Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.
3
Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).治疗原始浆细胞样树突细胞肿瘤（BPDCN）中 tagraxofusp 的作用。
Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17.
4
Infiltrative plaques on the temple. Blastic plasmacytoid dendritic cell neoplasm (BPDCN).颞部浸润性斑块。母细胞性浆细胞样树突状细胞肿瘤（BPDCN）。
Pediatr Dermatol. 2015 Mar-Apr;32(2):283-4. doi: 10.1111/pde.12465.
5
Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature.异基因造血干细胞移植在伴有皮肤累及的儿童原始浆细胞样树突状细胞瘤完全缓解 1 期中的作用：病例报告及文献复习。
Pediatr Blood Cancer. 2013 Nov;60(11):E140-2. doi: 10.1002/pbc.24622. Epub 2013 Jun 20.
6
Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.塔格拉索夫，一种用于治疗母细胞样浆细胞样树突状细胞瘤的新型靶向CD123的细胞毒素。
Drugs Today (Barc). 2019 Dec;55(12):735-742. doi: 10.1358/dot.2019.55.12.3058917.
7
New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.在原始浆细胞样树突细胞肿瘤的遗传学和靶向治疗方面的新视角。
Crit Rev Oncol Hematol. 2020 May;149:102928. doi: 10.1016/j.critrevonc.2020.102928. Epub 2020 Mar 2.
8
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.治疗原始浆细胞样树突细胞肿瘤（BPDCN）患者：重点关注 tagraxofusp 的使用和临床注意事项。
Leuk Lymphoma. 2024 May;65(5):548-559. doi: 10.1080/10428194.2024.2305288. Epub 2024 Feb 23.
9
Dendritic Cell Leukemia: a Review.树突状细胞白血病：综述。
Curr Oncol Rep. 2020 May 15;22(6):55. doi: 10.1007/s11912-020-00921-y.
10
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.塔格拉索夫（Tagraxofusp）与阿扎胞苷联合使用是异基因造血干细胞移植后复发的浆细胞样树突状细胞瘤的有效治疗选择。
Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2.
引用本文的文献
1
Some Examples of Bacterial Toxins as Tools.一些细菌毒素作为工具的例子。
Toxins (Basel). 2024 Apr 23;16(5):202. doi: 10.3390/toxins16050202.
2
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.在急性髓细胞白血病中，tagraxofusp 联合阿扎胞苷和/或 venetoclax 的 1b 期临床试验。
Blood Adv. 2024 Feb 13;8(3):591-602. doi: 10.1182/bloodadvances.2023011721.
3
Plasmacytoid dendritic cell neoplasms.浆细胞样树突状细胞瘤
Blood Res. 2023 Apr 30;58(S1):90-95. doi: 10.5045/br.2023.2023052.
4
CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.CD123及其他：如何靶向浆细胞样树突状细胞肿瘤的细胞表面
Cancers (Basel). 2022 May 3;14(9):2287. doi: 10.3390/cancers14092287.
5
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.去甲基化药物与免疫疗法：急性髓系白血病和骨髓增生异常综合征中的治疗协同作用
Front Oncol. 2021 Feb 25;11:624742. doi: 10.3389/fonc.2021.624742. eCollection 2021.
6
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.批准 tagraxofusp-erzs 用于治疗原始浆细胞样树突状细胞瘤。
Blood Adv. 2020 Aug 25;4(16):4020-4027. doi: 10.1182/bloodadvances.2019000173.
7
A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature.浆细胞样树突状细胞肿瘤的一种新姑息治疗方法：1例病例报告及文献复习
J Int Med Res. 2019 Oct;47(10):5281-5288. doi: 10.1177/0300060519871860. Epub 2019 Sep 17.
8
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.DNA 甲基转移酶抑制克服了 CD123 靶向治疗耐药性的二氢嘧啶酶途径缺陷。
J Clin Invest. 2019 Nov 1;129(11):5005-5019. doi: 10.1172/JCI128571.
9
Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.针对具有特定糖基化模式的嵌合 122A2 抗体选择的表达 CD303 的靶标，提高了体外和体内活性。
MAbs. 2018 May/Jun;10(4):651-663. doi: 10.1080/19420862.2018.1451283. Epub 2018 Apr 10.
10
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.复发难治性急性髓系白血病的当前治疗方法
J Clin Med. 2015 Apr;4(4):665-95. doi: 10.3390/jcm4040665.
本文引用的文献
1
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.托法替尼抑制了啮齿类动物宿主对蛋白治疗药物的抗体应答。
J Immunol. 2014 Jul 1;193(1):48-55. doi: 10.4049/jimmunol.1400063. Epub 2014 Jun 2.
2
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.针对白细胞介素-3受体的靶向疗法SL-401在母细胞样浆细胞样树突状细胞肿瘤患者中的活性。
Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.
3
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.通过鉴定和沉默人 T 细胞表位降低免疫原性的用于癌症治疗的重组免疫毒素。
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8571-6. doi: 10.1073/pnas.1405153111. Epub 2014 May 5.
4
Immunotoxins for leukemia.免疫毒素治疗白血病。
Blood. 2014 Apr 17;123(16):2470-7. doi: 10.1182/blood-2014-01-492256. Epub 2014 Feb 27.
5
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.CD123 是血液恶性肿瘤中的一种膜生物标志物和治疗靶点。
Biomark Res. 2014 Feb 10;2(1):4. doi: 10.1186/2050-7771-2-4.
6
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.抗 CD22 重组免疫毒素 moxetumomab pasudotox（CAT-8015 或 HA22）治疗毛细胞白血病患者的 I 期临床试验。
J Clin Oncol. 2012 May 20;30(15):1822-8. doi: 10.1200/JCO.2011.38.1756. Epub 2012 Feb 21.
7
Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.正常骨髓B细胞前体（“造血细胞”）和B淋巴细胞白血病母细胞上CD123和CD34的不同表达模式。
Am J Clin Pathol. 2009 Oct;132(4):573-80. doi: 10.1309/AJCPO4DS0GTLSOEI.
8
Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?浆细胞样树突状细胞白血病/淋巴瘤：会成为一个明确的实体吗？
Br J Haematol. 2007 Feb;136(4):539-48. doi: 10.1111/j.1365-2141.2006.06458.x.
9
Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin.白喉毒素与抗淋巴细胞球蛋白结合后，其对淋巴母细胞样细胞的毒性增强。
Nature. 1978 Feb 23;271(5647):752-5. doi: 10.1038/271752a0.
Zotero 插件